Brought to you by 
iZumi Bio and Pierian merge to form iPierian
14 Jul 2009
Executive Summary
Stem cell companies iZumi Bio and Pierian (formed by faculty at Harvard University) have merged to form iPierian, an entity that will focus on using induced pluripotent stem (iPS) cells as therapies for diseases that are hard to treat.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
iZumi Bio and Pierian merge to form iPierian
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice